MedPath

Clinical Trial News

Immix Biopharma Expands NXC-201 Clinical Trial Sites for AL Amyloidosis

  • Immix Biopharma broadens its NEXICART-2 trial for relapsed/refractory AL Amyloidosis by incorporating new clinical sites, enhancing patient accessibility.
  • The expansion includes leading AL Amyloidosis programs at Cleveland Clinic, UC Davis, and Sutter Health, with Memorial Sloan Kettering Cancer Center as the lead site.
  • NXC-201, a BCMA-targeted CAR-T cell therapy, demonstrated a 92% overall response rate in an ex-U.S. trial, showing promise for this challenging disease.
  • The NEXICART-2 trial aims to evaluate the safety and efficacy of NXC-201 in patients who have not previously received BCMA-targeted therapy.

Study of NXC-201 CAR-T in Patients With Light Chain (AL) Amyloidosis

NCT06097832RecruitingPhase 1
Nexcella Inc.
Posted 6/5/2024

NXC-201 (formerly HBI0101) Multiple Myeloma

NCT04720313Active, Not RecruitingPhase 1
Hadassah Medical Organization
Posted 1/1/2021

EmVenio Research Expands Clinical Trial Access with New Sites in Dallas and Atlanta

  • EmVenio Research has launched clinical research sites within Prime Healthcare hospitals in Dallas and Atlanta to broaden patient access to trials.
  • The new sites aim to engage community-based participant populations, addressing the lack of research opportunities in underrepresented demographics.
  • EmVenio and Prime Healthcare prioritize analyzing social determinants of health to bring clinical research as a care option to underserved communities.
  • Additional research sites are planned for Prime hospitals in Michigan and Kansas in 2024, with further expansion expected in 2025.

Robert Salata, Leading Infectious Disease Expert, Dies at 72

  • Dr. Robert Salata, a distinguished figure in infectious disease research and education at University Hospitals and Case Western Reserve University, passed away on August 26 at the age of 72.
  • As Chief of Infectious Diseases and HIV Medicine, Dr. Salata spearheaded crucial research, including pivotal roles in Remdesivir and Pfizer COVID-19 vaccine clinical trials.
  • His collaborative efforts led to the establishment of a research hub in Kampala, Uganda, fostering global health initiatives and medical advancements.
  • Dr. Salata's legacy includes mentoring numerous physicians and making significant contributions to understanding and combating infectious diseases, both locally and globally.

Hyundai Bioscience Initiates Phase 3 Trial of Xafty for High-Risk COVID-19 Patients

  • Hyundai Bioscience has submitted an IND application to the MFDS for a Phase 3 clinical trial of Xafty targeting high-risk COVID-19 patients.
  • The trial aims to address the urgent need for safe and effective treatments for high-risk individuals who cannot take Paxlovid due to drug interactions.
  • Xafty previously demonstrated efficacy and safety in mild-to-moderate COVID-19 patients, with promising results in a high-risk subgroup analysis.
  • The Phase 3 trial will involve 290 participants and focus on outpatient visits to expedite recruitment and reduce costs.

Inclisiran Demonstrates Significant LDL-C Lowering in V-MONO Trial

• Inclisiran monotherapy significantly reduced LDL-C levels compared to placebo and ezetimibe in patients with low to moderate ASCVD risk. • The Phase III V-MONO study met its primary endpoints, showcasing inclisiran's superiority in LDL-C reduction. • Novartis plans to present the V-MONO trial results to regulatory agencies, including the FDA, for potential label expansion. • The V-MONO trial is part of the larger VictORION program, which includes over 60,000 patients across more than 30 trials.

Efficacy and Safety of Inclisiran as Monotherapy in Patients With Primary Hypercholesterolemia Not Receiving Lipid-lowering Therapy.

NCT05763875CompletedPhase 3
Novartis Pharmaceuticals
Posted 3/15/2023

Trial to Assess the Effect of Long Term Dosing of Inclisiran in Subjects With High CV Risk and Elevated LDL-C

NCT03814187CompletedPhase 3
Novartis Pharmaceuticals
Posted 4/16/2019

Experts Call for Technology-Driven Solutions to Boost Minority Representation in CLL Clinical Trials

• Clinical trials significantly underrepresent America's diverse population, with particular challenges in engaging Black patients due to historical trust issues in medical interventions.
• Technology tools are being implemented to identify and alert research teams about potential trial candidates, enabling more targeted outreach and education efforts.
• Healthcare providers are working to build trust and ensure better representation by setting specific diversity targets in clinical trials while leveraging digital solutions for patient identification.

Leading Experts to Host Webinar on Scientific Storytelling in Medical Publications

  • AstraZeneca, Taylor & Francis, and HCG executives will convene on September 18th to discuss the integration of storytelling techniques in medical publications and their impact on healthcare communication.
  • The webinar aims to explore how scientific storytelling can enhance health equity through plain-language content and publication extenders, making complex medical information more accessible to diverse audiences.
  • Industry experts, including Nicole Parker from HCG and David Ginkel from AstraZeneca, will share insights on implementing storytelling strategies while maintaining scientific rigor in peer-reviewed publications.

TCT 2024 to Showcase Groundbreaking Cardiovascular Research

  • TCT 2024 will feature 25 late-breaking clinical trials, presenting novel interventions, drugs, and techniques for cardiovascular disease treatment.
  • The EARLY TAVR trial examines transcatheter aortic valve replacement for asymptomatic severe aortic stenosis, potentially changing treatment paradigms.
  • The CLEAR SYNERGY trial investigates colchicine and spironolactone's impact on myocardial infarction patients, offering insights into anti-inflammatory therapies.
  • TRISCEND II will compare transcatheter valve replacement with optimal medical therapy for severe tricuspid regurgitation, addressing a critical unmet need.

Semaglutide Trial Launched to Improve Heart Health in Type 1 Diabetes

  • A clinical trial, RESET1, is underway in Sydney to investigate semaglutide's impact on heart health in adults with type 1 diabetes.
  • The study aims to determine if semaglutide can improve cardiovascular risk factors like high blood pressure and cholesterol in T1D patients.
  • Participants will receive weekly semaglutide or a placebo for 26 weeks, with researchers monitoring heart health and metabolic measures.
  • The trial seeks adults aged 25-70 with T1D, a BMI over 25, and heart disease risk factors to participate in the research.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.